Hereditary Angioedema Treatment Market Size, Share and Industry Analysis by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), By Application (Prophylaxis, Treatment), By Route of Administration (IV, Subcutaneous), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, others), and Regional Forecast 2025-2032

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions andAssumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Key Strategies of Leading Market Players

4.2 Epidemiology of Hereditary Angioedema – for Key Countries

4.3 Pipeline Analysis

4.4 Introduction of New Products/Approvals (by Major Players)

5. Global Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2024-2032

5.1. Key Findings / Summary

5.2. Market Analysis,Insights and Forecast – By Drug Class

5.2.1 C-1 Esterase Inhibitors

5.2.2 Bradykynin Receptor Antagonist

5.2.3 Kallikrein Inhibitors

5.3. Market Analysis,Insights and Forecast – By Application

5.3.1 Prophylaxis

5.3.2 Treatment

5.4 Market Analysis,Insights and Forecast – By Route of Administration

5.4.1 IV

5.4.2 Subcutaneous

5.5. Market Analysis,Insights and Forecast – By Distribution Channel

5.5.1 Hospital Pharmacy

5.5.2 Retail Pharmacy

5.5.3 Others

5.6. Market Analysis,Insights and Forecast – By Region

5.6.1 North America

5.6.2 Europe

5.6.3 Rest of the World

6. North America  Hereditary Angioedema Treatment  Market Analysis, Insights andForecast, 2024-2032

6.1. Key Findings / Summary

6.2. Market Analysis – By Drug Class

6.2.1 C-1 Esterase Inhibitors

6.2.2 Bradykynin Receptor Antagonist

6.2.3 Kallikrein Inhibitors

6.3. Market Analysis – By Application

6.3.1 Prophylaxis

6.3.2 Treatment

6.4. Market Analysis – By Route of Administration

6.4.1 IV

6.4.2 Subcutaneous

6.5. Market Analysis – By Distribution Channel

6.5.1 Hospital Pharmacy

6.5.2 Retail Pharmacy

6.5.3 Others

6.6. Market Analysis – By Country

6.6.1 U.S

6.6.2 Canada

7. Europe Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2024-2032

7.1. Key Findings / Summary

7.2. Market Analysis – By Drug Class

7.2.1 C-1 Esterase Inhibitors

7.2.2 Bradykynin Receptor Antagonist

7.2.3 Kallikrein Inhibitors

7.3. Market Analysis – By Application

7.3.1 Prophylaxis

7.3.2 Treatment

7.4. Market Analysis – By Route of Administration

7.4.1 IV

7.4.2 Subcutaneous

7.5. Market Analysis – By Distribution Channel

7.5.1 Hospital Pharmacy

7.5.2 Retail Pharmacy

7.5.3 Others

7.6. Market Analysis – By Country / Sub-region

7.6.1 UK

7.6.2 Germany

7.6.3 France

7.6.4 Italy

7.6.5 Spain

7.6.6 Scandinavia

7.6.7 Rest of Europe

8. Rest of the World Hereditary Angioedema Treatment  Market Analysis, Insights and Forecast,2024-2032

8.1. Key Findings / Summary

8.2. Market Analysis – By Drug Class

8.2.1 C-1 Esterase Inhibitors

8.2.2 Bradykynin Receptor Antagonist

8.2.3 Kallikrein Inhibitors

8.3. Market Analysis – By Application

8.3.1 Prophylaxis

8.3.2 Treatment

8.4. Market Analysis – By Route of Administration

8.4.1 IV

8.4.2 Subcutaneous

8.5. Market Analysis – By Distribution Channel

8.5.1 Hospital Pharmacy

8.5.2 Retail Pharmacy

8.5.3 Others

9. Competitive Analysis

9.1. Key Industry Developments

9.2. Global Market Share Analysis (2018)

9.3. Competition Dashboard

9.4. Comparative Analysis –Major Players

9.5. Company Profiles(Overview, Products & services, SWOT analysis, Recent developments,strategies, financials (based on availability))

9.5.1 CSL Behring

9.5.2 Shire plc.

9.5.3 Pharming Group NV

9.5.4 BIOCRYST PHARMACEUTICALS, INC.

9.5.5 Ionis Pharmaceuticals, Inc.

9.5.6 Attune Pharmaceuticals

9.5.7 Arrowhead Pharmaceuticals, Inc.

9.5.8 Adverum

9.5.9 Other prominent players

10. Strategic Recommendations